VERA
Vera Therapeutics, Inc. [VERA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VERA Stock Summary
Top 10 Correlated Stocks
VERA
In the News
VERA Financial details
Company Rating
Neutral
Market Cap
2.63B
Income
-95.68M
Revenue
0
Book val./share
2.29
Cash/share
3.62
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.33
Forward P/E
-
PEG
2.61
P/S
-
P/B
6.9
P/C
10.3
P/FCF
-9.69
Quick Ratio
6.5
Current Ratio
6.97
Debt / Equity
0.51
LT Debt / Equity
0.49
-
-
EPS (TTM)
-2.28
EPS next Y
-
EPS next Q
-
EPS this Y
-32.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
28.89%
-
-
-
-
SMA20
-
SMA50
13.16%
SMA100
230.77%
Inst Own
56.09%
Inst Trans
0.55%
ROA
-58%
ROE
-82%
ROC
-0.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.05-50.78
52W High
-25.41%
52W Low
+521.58%
RSI
43
Rel Volume
0.71
Avg Volume
1.38M
Volume
986.66K
Perf Week
-23.61%
Perf Month
-15.81%
Perf Quarter
273.7%
Perf Half Y
245.32%
-
-
-
-
Beta
1.049
-
-
Volatility
3.68%, 2.94%
Prev Close
-5.53%
Price
37.295
Change
-5.89%
VERA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -3.46 | -14.4 | -1.53 | -3.35 | -2.25 | |
| Operating cash flow per share | -3.01 | -9.39 | -1.11 | -2.54 | -2.16 | |
| Free cash flow per share | -3.04 | -9.41 | -1.11 | -2.55 | -2.16 | |
| Cash per share | 0.93 | 14.47 | 3.74 | 6.99 | 3.76 | |
| Book value per share | -10.68 | -24.1 | 3.27 | 2.89 | 2.38 | |
| Tangible book value per share | -10.68 | -24.1 | 3.27 | 2.89 | 2.38 | |
| Share holders equity per share | -10.68 | -24.1 | 3.27 | 2.89 | 2.38 | |
| Interest debt per share | 0.05 | 0.05 | 0.23 | 1.21 | 1.14 | |
| Market cap | 39.36M | 42.64M | 568.54M | 514.14M | 656.83M | |
| Enterprise value | 36.3M | -11.01M | 493.79M | 430.78M | 664.86M | |
| P/E ratio | -3.32 | -0.8 | -17.43 | -5.77 | -6.84 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -3.83 | -1.23 | -23.98 | -7.61 | -7.13 | |
| PFCF ratio | -3.78 | -1.22 | -23.98 | -7.6 | -7.12 | |
| P/B Ratio | -1.08 | -0.48 | 8.17 | 6.69 | 6.46 | |
| PTB ratio | -1.08 | -0.48 | 8.17 | 6.69 | 6.46 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.29 | 0.22 | -14.35 | -4.74 | -6.4 | |
| EV to operating cash flow | -3.53 | 0.32 | -20.83 | -6.37 | -7.21 | |
| EV to free cash flow | -3.49 | 0.32 | -20.83 | -6.37 | -7.21 | |
| Earnings yield | -0.3 | -1.25 | -0.06 | -0.17 | -0.15 | |
| Free cash flow yield | -0.26 | -0.82 | -0.04 | -0.13 | -0.14 | |
| Debt to equity | 0 | 0 | 0.07 | 0.41 | 0.51 | |
| Debt to assets | 0.02 | 0 | 0.06 | 0.24 | 0.3 | |
| Net debt to EBITDA | 0.28 | 1.07 | 2.17 | 0.92 | -0.08 | |
| Current ratio | 3.36 | 22.55 | 10.73 | 4.91 | 7.42 | |
| Interest coverage | -234.53 | -314.7 | -1.72K | -91.64 | 26.94 | |
| Income quality | 0.87 | 0.65 | 0.73 | 0.76 | 0.96 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.25 | -0.39 | 0 | 0.07 | 0.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 28.85 | 88.37 | 10.62 | 14.77 | 10.97 | |
| ROIC | 0.33 | 0.58 | -0.46 | -0.79 | -0.66 | |
| Return on tangible assets | -2.2 | -0.98 | -0.39 | -0.68 | -0.55 | |
| Graham Net | -11.32 | -24.26 | 3.08 | 4.94 | 2.03 | |
| Working capital | 2.51M | 51.86M | 74.85M | 100.1M | 143.24M | |
| Tangible asset value | -36.55M | -89.35M | 69.59M | 76.91M | 101.69M | |
| Net current asset value | -38.36M | -89.64M | 68.38M | 71.17M | 91.68M | |
| Invested capital | 0 | 0 | 0.07 | 0.41 | 0.51 | |
| Average receivables | 0 | 26K | 26K | 0 | 0 | |
| Average payables | 0 | 625.5K | 1.15M | 6.69M | 11.55M | |
| Average inventory | 0 | 236K | 236K | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 245.25 | 1.32K | 2.87K | -5.17K | -2.18K | |
| Days of inventory on hand | 0 | 686.37 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.49 | 0.28 | 0.13 | -0.07 | -0.17 | |
| Inventory turnover | 0 | 0.53 | 0 | 0 | 0 | |
| ROE | 0.32 | 0.6 | -0.47 | -1.16 | -0.94 | |
| Capex per share | -0.04 | -0.03 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.17 | -0.79 | -0.46 | -0.45 | -0.58 | |
| Operating cash flow per share | -0.76 | -0.7 | -0.4 | -0.52 | -0.57 | |
| Free cash flow per share | -0.76 | -0.7 | -0.4 | -0.52 | -0.57 | |
| Cash per share | 4.12 | 5.23 | 4.09 | 3.61 | 3.62 | |
| Book value per share | 2.77 | 4.19 | 3.17 | 2.79 | 2.29 | |
| Tangible book value per share | 2.77 | 4.19 | 3.17 | 2.79 | 2.29 | |
| Share holders equity per share | 2.77 | 4.19 | 3.17 | 2.79 | 2.29 | |
| Interest debt per share | 1.15 | 0.84 | 0.7 | 0.64 | 1.2 | |
| Market cap | 537.95M | 292.3M | 710.53M | 608.22M | 683.67M | |
| Enterprise value | 525.77M | 185.6M | 706.73M | 610.3M | 691.7M | |
| P/E ratio | -4.15 | -2.46 | -8.81 | -7.56 | -6.66 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -25.42 | -11.12 | -39.98 | -26.48 | -27.19 | |
| PFCF ratio | -25.41 | -11.12 | -39.98 | -26.48 | -27.12 | |
| P/B Ratio | 6.99 | 1.85 | 5.06 | 4.92 | 6.72 | |
| PTB ratio | 6.99 | 1.85 | 5.06 | 4.92 | 6.72 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -16.55 | -5.94 | -36.77 | -28.05 | -25 | |
| EV to operating cash flow | -24.85 | -7.06 | -39.77 | -26.57 | -27.51 | |
| EV to free cash flow | -24.84 | -7.06 | -39.77 | -26.57 | -27.44 | |
| Earnings yield | -0.06 | -0.1 | -0.03 | -0.03 | -0.04 | |
| Free cash flow yield | -0.04 | -0.09 | -0.03 | -0.04 | -0.04 | |
| Debt to equity | 0.41 | 0.19 | 0.21 | 0.24 | 0.51 | |
| Debt to assets | 0.24 | 0.15 | 0.15 | 0.17 | 0.3 | |
| Net debt to EBITDA | 0.38 | 3.41 | 0.2 | -0.1 | -0.29 | |
| Current ratio | 4.91 | 8.69 | 7.1 | 6.97 | 7.42 | |
| Interest coverage | -56.06 | -35.76 | -24.04 | 23.07 | -25.59 | |
| Income quality | 0.65 | 0.87 | 0.88 | 1.14 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0.01 | 0 | 0 | 0 | 0.1 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.52 | 8.63 | 5.7 | 5.33 | 5.45 | |
| ROIC | -0.29 | -0.16 | -0.14 | -0.15 | -0.17 | |
| Return on tangible assets | -0.25 | -0.14 | -0.1 | -0.11 | -0.15 | |
| Graham Net | 2.16 | 3.86 | 2.85 | 2.44 | 1.95 | |
| Working capital | 100.1M | 180.92M | 163.78M | 147M | 143.24M | |
| Tangible asset value | 76.91M | 157.71M | 140.52M | 123.71M | 101.69M | |
| Net current asset value | 71.17M | 152.55M | 135.96M | 119.71M | 91.68M | |
| Invested capital | 0.41 | 0.19 | 0.21 | 0.24 | 0.51 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 9.5M | 8.66M | 9.3M | 12.79M | 11.71M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | -947.31 | 0 | 0 | -1.58K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | -0.1 | 0 | 0 | -0.06 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.42 | -0.19 | -0.14 | -0.16 | -0.25 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
VERA Frequently Asked Questions
What is Vera Therapeutics, Inc. stock symbol ?
Vera Therapeutics, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol VERA
What is Vera Therapeutics, Inc. stock quote today ?
Vera Therapeutics, Inc. stock price is $37.295 today.
Is Vera Therapeutics, Inc. stock public?
Yes, Vera Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.38M
- Market Capitalization 2.63B
- Employee 51
- CEO Dr. Marshall W. Fordyce M.D.
- Headquarters Brisbane,CA,US
- IPO Date 2021-05-14
-
Website
https://veratx.com 
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
